Antiretroviral dynamics determines HIV evolution and predicts therapy outcome

Nature Medicine

Volumn 18, Issue 9, 2012, Pages 1378-1385

  Rosenbloom, Daniel I S ^a   Hill, Alison L ^a,b   Rabi, S Alireza ^c   Siliciano, Robert F ^c,d   Nowak, Martin A ^a  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; NELFINAVIR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; TIPRANAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG HALF LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIROGENESIS; VIRUS REPLICATION; VIRUS STRAIN; ANTIVIRAL RESISTANCE; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG COMBINATION; EVOLUTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; METHODOLOGY; MUTATION; REPRODUCTIVE FITNESS; SPECIES DIFFERENCE;

ANTI-RETROVIRAL AGENTS; BIOLOGICAL EVOLUTION; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENETIC FITNESS; HIV; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; MODELS, BIOLOGICAL; MUTATION; SPECIES SPECIFICITY; TREATMENT OUTCOME;

EID: 84868664375     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2892     Document Type: Article

References (65)

1. Palella, F.J. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338, 853-860 (1998).
2. Vanhove, G.F., Schapiro, J.M., Winters, M.A., Merigan, T.C. & Blaschke, T.F. Patient compliance and drug failure in protease inhibitor monotherapy. J. Am. Med. Assoc. 276, 1955-1956 (1996).
3. Gardner, E.M., Burman, W.J., Steiner, J.F., Anderson, P.L. & Bangsberg, D.R. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS 23, 1035-1046 (2009).
4. Maggiolo, F. et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI-or PI-treated patients. HIV Clin. Trials 8, 282-292 (2007).
5. Harrigan, P.R. et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J. Infect. Dis. 191, 339-347 (2005).
6. US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults & Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (2011).
7. Arribas, J.R. et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 24, 223-230 (2010).
8. Taiwo, B. et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG a5262). AIDS 25, 2113-2122 (2011).
9. Havlir, D.V. et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. J. Am. Med. Assoc. 283, 229-234 (2000).
10. Pulido, F., Arribas, J., Hill, A. & Moecklinghoff, C. No evidence for evolution of genotypic resistance after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues. AIDS Res. Hum. Retroviruses published online, doi:10.1089/aid.2011.0256 (20 April 2012).
11. Condra, J.H. Resistance to HIV protease inhibitors. Haemophilia 4, 610-615 (1998).
12. Kempf, D.J. et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J. Infect. Dis. 189, 51-60 (2004).
13. Noë, A., Plum, J. & Verhofstede, C. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J. Antimicrob. Chemother. 55, 410-412 (2005).
14. Nowak, M.A. & May, R.M.C. Virus Dynamics: Mathematical Principles of Immunology and Virology (Oxford University Press, USA, 2000).
15. Chou, T.-C. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J. Theor. Biol. 59, 253-276 (1976).
16. Shen, L. et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14, 762-766 (2008).
17. Sampah, M.E.S., Shen, L., Jilek, B.L. & Siliciano, R.F. Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc. Natl. Acad. Sci. USA 108, 7613-7618 (2011).
18. Drlica, K. The mutant selection window and antimicrobial resistance. J. Antimicrob. Chemother. 52, 11-17 (2003).
19. Drlica, K. & Zhao, X. Mutant selection window hypothesis updated. Clin. Infect. Dis. 44, 681-688 (2007).
20. Wahl, L.M. & Nowak, M.A. Adherence and drug resistance: predictions for therapy outcome. Proc. Bio. Sci. 267, 835-843 (2000).
21. Wu, H. et al. Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J. Acquir. Immune Defic. Syndr. 39, 272-283 (2005).
22. Smith, R.J. Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges? Proc. Biol. Sci. 273, 617-624 (2006).
23. Rong, L., Feng, Z. & Perelson, A.S. Emergence of HIV-1 drug resistance during antiretroviral treatment. Bull. Math. Biol. 69, 2027-2060 (2007).
24. Bangsberg, D.R., Moss, A.R. & Deeks, S.G. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J. Antimicrob. Chemother. 53, 696-699 (2004).
25. Pérez-Valero, I. & Arribas, J.R. Protease inhibitor monotherapy. Curr. Opin. Infect. Dis. 24, 7-11 (2011).
26. Bangsberg, D.R., Kroetz, D.L. & Deeks, S.G. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr. HIV/AIDS Rep. 4, 65-72 (2007).
27. Bliss, C.I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26, 585-615 (1939).
28. Jilek, B.L. et al. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat. Med. 18, 446-451 (2012).
29. Shen, L. et al. A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. Sci. Transl. Med. 3, 91ra63 (2011).
30. Bangsberg, D.R. et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20, 223-231 (2006).
31. Nijhuis, M. et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med. 4, e36 (2007).
32. Parry, C.M. et al. Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J. Virol. 83, 9094-9101 (2009).
33. Dam, E. et al. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog. 5, e1000345 (2009).
34. Gupta, R.K. et al. Full length HIV-1 gag determines protease inhibitor susceptibility within in vitro assays. AIDS 24, 1651-1655 (2010).
35. Gardner, E.M. et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 22, 75-82 (2008).
36. Michel, J.-B., Yeh, P.J., Chait, R., Moellering, R.C. & Kishony, R. Drug interactions modulate the potential for evolution of resistance. Proc. Natl. Acad. Sci. USA 105, 14918-14923 (2008).
37. Cheeseman, S.H. et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8, 141-151 (1995).
38. Ruxrungtham, K. et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med. 9, 883-896 (2008).
39. Bonhoeffer, S. & Nowak, M.A. Pre-existence and emergence of drug resistance in HIV-1 infection. Proc. Biol. Sci. 264, 631-637 (1997).
40. Paredes, R. et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J. Infect. Dis. 201, 662-671 (2010).
41. Jourdain, G. et al. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure. Clin. Infect. Dis. 50, 1397-1404 (2010).
42. Simen, B.B. et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 199, 693-701 (2009).
43. Gupta, R.K. et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under who guidelines: a systematic review and meta-analysis. Lancet Infect. Dis. 9, 409-417 (2009).
44. Hoffmann, C.J. et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype c during first-line antiretroviral therapy in South Africa. Clin. Infect. Dis. 49, 1928-1935 (2009).
45. Parienti, J.-J. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS ONE 3, e2783 (2008).
46. Parienti, J.-J. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin. Infect. Dis. 50, 1192-1197 (2010).
47. Liu, H. et al. Repeated measures analyses of dose timing of antiretroviral medication and its relationship to HIV virologic outcomes. Stat. Med. 26, 991-1007 (2007).
48. Kastrissios, H. et al. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS 12, 2295-2303 (1998).
49. Sigal, A. et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477, 95-98 (2011).
50. Kepler, T.B. & Perelson, A.S. Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc. Natl. Acad. Sci. USA 95, 11514-11519 (1998).
51. Schnell, G., Price, R.W., Swanstrom, R. & Spudich, S. Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J. Virol. 84, 2395-2407 (2010).
52. van Marle, G. et al. Compartmentalization of the gut viral reservoir in HIV-1 infected patients. Retrovirology 4, 87 (2007).
53. Best, B.M. et al. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J. Antimicrob. Chemother. 66, 354-357 (2011).
54. Hill, A.L., Rosenbloom, D.I.S. & Nowak, M.A. Evolutionary dynamics of HIV at multiple spatial and temporal scales. J. Mol. Med. 90, 543-561 (2012).
55. Hirsch, M.S. et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. J. Am. Med. Assoc. 283, 2417-2426 (2000).
56. Lima, V.D. et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS 22, 2371-2380 (2008).
57. Boltz, V.F. et al. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc. Natl. Acad. Sci. USA 108, 9202-9207 (2011).
58. Nowak, M.A. et al. Antigenic diversity thresholds and the development of AIDS. Science 254, 963-969 (1991).
59. Shankarappa, R. et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 73, 10489-10502 (1999).
60. Neher, R.A. & Leitner, T. Recombination rate and selection strength in HIV intra-patient evolution. PLoS Comput. Biol. 6, e1000660 (2010).
61. Zhao, X. & Drlica, K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 185, 561-565 (2002).
62. Gullberg, E. et al. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog. 7, e1002158 (2011).
63. Sedaghat, A.R., Dinoso, J.B., Shen, L., Wilke, C.O. & Siliciano, R.F. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc. Natl. Acad. Sci. USA 105, 4832-4837 (2008).
64. Ribeiro, R.M. et al. Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J. Virol. 84, 6096-6102 (2010).
65. Ribeiro, R.M., Bonhoeffer, S. & Nowak, M.A. The frequency of resistant mutant virus before antiviral therapy. AIDS 12, 461-465 (1998).